Hansoh Pharmaceutical: Xinyue®'s third indication approved and launched for the treatment of adult patients with generalized myasthenia gravis

LightningPacketLoss · 2026-03-28T04:34:37+00:00

Hansoh Pharmaceutical announced that its innovative drug XinYue® (Inebilizumab Injection) has received NMPA approval, with an additional indication for the combined treatment of adult generalized myasthenia gravis positive for anti-AChR or anti-MuSK antibodies. This is the third rare disease indication approved for this drug in China.

LightningPacketLoss

2026-03-28 04:34:37

Abstract generation in progress

On March 27, Hansoh Pharmaceutical Group Co., Ltd. announced that its innovative drug Xinyue® (inelizumab injection) received a drug registration certificate issued by the National Medical Products Administration (NMPA), approving an additional indication: this product, in combination with conventional therapeutic drugs, is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) antibodies or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

Previously, Xinyue® had already been approved for the treatment of two rare diseases: neuromyelitis optica spectrum disorder (NMOSD) and immunoglobulin G4-related disease (IgG4-RD). This approval of gMG is the third rare-disease indication for Xinyue® that has been approved in China.

(Hansoh Pharmaceutical announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes